Swaminathan P. Iyer, M.D.
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1996 | Bangalore Medical College, Bangalore, IND, MBBS, Internal Medicine |
Postgraduate Training
| 2000-2003 | Clinical Fellowship, Hematology/Oncology, Jackson Memorial Hospital University of Miami, Miami, FL |
| 2000-2000 | Chief Medical Resident, Internal Medicine, Wayne State University, Detroit, MI |
| 1997-2000 | Clinical Residency, Internal Medicine, Wayne State University, Detroit, MI |
| 1996-1996 | PG Resident, Internal Medicine, All India Institute of Medical Sciences, New Delhi |
| 1996-1996 | PG Resident, Medical Education and Research, Jawaharlal Institute for Post Graduate, Pondicherry |
| 1994-1995 | Research Internship, Bangalore Medical College, Bangalore |
Board Certifications
| 2004 | ABIM-Diplomate in Hematology |
| 2003 | ABIM Diplomate in Medical Oncology |
| 2000 | American Board of Internal Medicine (ABIM) Diplomate in Internal Medicine |
| 1996 | Educational Commission on Foreign Medical Graduates (ECFMG) |
Experience & Service
Other Appointments/Responsibilities
Chief, Section of Hematology, Houston Methodist Cancer Center, Houston, TX, 2017 - 2018
Professor of Medicine, Institute of Academic Medicine, Houston Methodist, Houston, TX, 2017 - 2018
Associate Professor of Medicine, Weill Cornell Medical College, New York City, NY, 2014 - 2018
Associate Professor of Medicine, Institute of Academic Medicine, Houston Methodist, Houston, TX, 2014 - 2016
Assistant Professor of Medicine, Institute of Academic Medicine, Houston, TX, 2011 - 2013
Staff Physician, Texas Transplant Institute, Methodist Hospital, San Antonio, TX, 2011 - 2011
Assistant Professor of Medicine, Cancer Therapy and Research Center, UT Health Science Center, San Antonio, TX, 2008 - 2011
Assistant Professor of Medicine, Lymphoma/Myeloma, Blood, and Marrow Transplant, Roswell Park Cancer Institute, Buffalo, NY, 2003 - 2008
Selected Publications
Peer-Reviewed Articles
- Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiat Res 190(3):322-329, 2018. e-Pub 2018. PMID: 29949442.
- Kelly KR, Friedberg JW, Park SI, McDonagh KT, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen PJ, Padmanabhan Iyer S, Stefanovic A, Bernstein SH, Weitman S, Karnad AB, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma. Clin Cancer Res. e-Pub 2018. PMID: 30082475.
- Chakraborty S, Pandita RK, Hambarde S, Mattoo AR, Charaka V, Ahmed KM, Iyer SP, Hunt CR, Pandita TK. SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair. iScience 2:123-135, 2018. PMID: 29888761.
- Sun K, Kasparian S, Iyer S, Pingali SR. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience 12:836, 2018. e-Pub 2018. PMID: 29910833.
- Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol 35(4):914-917, 2017. e-Pub 2016. PMID: 27402335.
- Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma 58(9):1-11, 2017. e-Pub 2017. PMID: 28140714.
- Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG, Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma 58(2):348-356, 2017. e-Pub 2016. PMID: 27389174.
- Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S . Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience 11:771, 2017. e-Pub 2017. PMID: 29062389.
- Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CS. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1534-8, 2016. e-Pub 2016. PMID: 26887657.
- Zhao N, Pei SN, Qi J, Zeng Z, Iyer SP, Lin P, Tung CH, Zu Y. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials 67:42-51, 2015. e-Pub 2015. PMID: 26204224.
- Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist 20(9):1084-91, 2015. e-Pub 2015. PMID: 26099743.
- Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3):366-75, 2014. e-Pub 2014. PMID: 25139740.
- Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 13(5):1142-54, 2014. e-Pub 2014. PMID: 24435446.
- Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Proia D, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28(5):1171-4, 2014. e-Pub 2014. PMID: 24413322.
- Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 72(4):897-908, 2013. e-Pub 2013. PMID: 23949430.
- Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, Bansal S. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 287(39):32875-80, 2012. e-Pub 2012. PMID: 22898820.
- Parmar S, Iyer SP. Bridging the gap in hematological malignancies. Expert Rev Hematol 5(3):257-9, 2012. PMID: 22780206.
Abstracts
- Iyer SP, Hunt CR, Pandita TK. Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet. Radiat Res 189(3):219-224, 2018. e-Pub 2017. PMID: 29261410.
Patient Reviews
CV information above last modified March 19, 2024